Z
38.83
-1.70 (-4.19%)
| Penutupan Terdahulu | 40.53 |
| Buka | 40.70 |
| Jumlah Dagangan | 166,011 |
| Purata Dagangan (3B) | 425,077 |
| Modal Pasaran | 2,084,362,240 |
| Harga / Pendapatan (P/E TTM) | 2.84 |
| Harga / Jualan (P/S) | 110.11 |
| Harga / Buku (P/B) | 10.76 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 12 Nov 2025 |
| Margin Operasi (TTM) | -373.30% |
| EPS Cair (TTM) | -3.89 |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.43% |
| Nisbah Semasa (MRQ) | 6.47 |
| Aliran Tunai Operasi (OCF TTM) | -137.62 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -77.73 M |
| Pulangan Atas Aset (ROA TTM) | -56.70% |
| Pulangan Atas Ekuiti (ROE TTM) | -115.47% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Bercampur | Bercampur |
| Biotechnology (Global) | Bercampur | Bercampur | |
| Stok | Zenas BioPharma, Inc. | Menaik | Menaik |
AISkor Stockmoo
1.3
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -3.0 |
| Purata Bergerak Teknikal | 2.5 |
| Osilator Teknikal | 4.0 |
| Purata | 1.25 |
|
Zenas BioPharma Inc is a clinical-stage biopharmaceutical company. Its I&I product candidate, obexelimab, is a bifunctional monoclonal antibody designed to bind both CD19 and FcyRIIb, which are present across B cell lineage, in order to inhibit the activity of cells that are implicated in many autoimmune diseases without depleting them. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| % Dimiliki oleh Orang Dalam | 21.20% |
| % Dimiliki oleh Institusi | 74.88% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 55.00 (Evercore ISI Group, 41.64%) | Beli |
| Median | 44.00 (13.31%) | |
| Rendah | 37.00 (Morgan Stanley, -4.71%) | Beli |
| Purata | 44.40 (14.35%) | |
| Jumlah | 5 Beli | |
| Harga Purata @ Panggilan | 32.87 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Evercore ISI Group | 26 Nov 2025 | 55.00 (41.64%) | Beli | 40.53 |
| Morgan Stanley | 13 Nov 2025 | 37.00 (-4.71%) | Beli | 35.66 |
| 28 Oct 2025 | 34.00 (-12.44%) | Beli | 30.19 | |
| Citigroup | 28 Oct 2025 | 46.00 (18.47%) | Beli | 30.19 |
| HC Wainwright & Co. | 28 Oct 2025 | 44.00 (13.31%) | Beli | 30.19 |
| 09 Oct 2025 | 30.00 (-22.74%) | Beli | 27.76 | |
| Wedbush | 09 Oct 2025 | 40.00 (3.01%) | Beli | 27.76 |
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2025 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |